乳がんにおける抗体-薬物結合:現在の耐性メカニズムと将来の組み合わせ戦略

Ping Xing^1,2,3, Chenghui Yang⁴, Hanwen Hu²

¹Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.

Cancer drug resistance (Alhambra, Calif.)

|August 22, 2025

まとめ

抗体-薬剤結合体 (ADC) は,がん細胞を標的とした乳がん治療において有望である. 耐性を克服し新しいペイロードを探求することは患者の治療結果を改善する鍵です

科学分野:

腫瘍学
薬理学について
バイオテクノロジー

背景:

抗体薬結合剤 (ADC) は"魔法の弾丸"のコンセプトにインスパイアされた標的型がん治療を提供します.
ADCは著しく進化し,新しい世代は乳がん治療において改善された臨床効果を示しています.
承認されたADCは,無進行生存期 (PFS) と全生存期 (OS) の改善に有効であることが示されています.

研究の目的:

乳がんにおけるADCのメカニズムと臨床結果の見直し
ADCに対する新たな耐性と既得耐性のメカニズムを調査する.
組み合わせ戦略を分析し,治療効果を高めるための新しいペイロードを特定する.

主な方法:

乳がんにおけるADCに関する臨床前および臨床研究の文献レビュー.
ADCの作用メカニズムと臨床試験データの分析
耐性メカニズムと組み合わせ治療の根拠の検討

主要な成果:

PFSとOSの改善を含む,乳がんにおいてADCは有意な臨床効果を示している.
いくつかのADC剤は臨床使用に承認されており,標的治療の進歩を表しています.
現在進行中の研究は,ADCを他の治療法と組み合わせることで,耐性を克服することに焦点を当てています.

結論:

ADCは乳がん治療における変革的なアプローチを表しています
ADCに対する耐性は,対処する必要がある重要な課題です.
組み合わせ戦略と新しいペイロードの開発は,ADCの有効性を最大化し,患者のアウトカムを改善するために不可欠です.

キーワード:

抗体-薬物結合体乳がん組み合わせの戦略トリートメント抵抗

さらに関連する動画

13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.9K

15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K

関連する概念動画

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.4K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:27

Combined Effects of Drugs: Synergism

4.7K

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

4.7K

01:14

Phase II Conjugation Reactions: Overview

311

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...

311

01:25

Drug-Receptor Bonds

3.3K

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...